A Phase 1, Open-label, Dose Escalation and Dose Expansion Study of CLN-978 in Patients With Relapsed/Refractory (R/R) B-cell Non-Hodgkin Lymphoma (B-NHL)

CLN-978-001 is a Phase 1, open-label, dose escalation and dose expansion study of CLN-978 in patients with Relapse/Refractory (R/R) B-cell Non-Hodgkin Lymphoma (B-NHL).

开始日期2023-05-31

申办/合作机构

Cullinan Oncology LLC

100 项与 CLN-978 相关的临床结果

登录后查看更多信息

100 项与 CLN-978 相关的转化医学

登录后查看更多信息

100 项与 CLN-978 相关的专利（医药）

登录后查看更多信息

项与 CLN-978 相关的文献（医药）

2023-12-01·Journal for immunotherapy of cancer

Correction: CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression

Article

2023-08-01·Journal for immunotherapy of cancer

CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression

Article

作者: Meetze, Kristan ; Baeuerle, Patrick A ; Mehta, Naveen K ; Li, Bochong ; Michaelson, Jennifer S

Background:

Despite significant progress in the development of T cell-engaging therapies for various B-cell malignancies, a high medical need remains for the refractory disease setting, often characterized by suboptimal target levels.

Methods:

To address this issue, we have developed a 65-kDa multispecific antibody construct, CLN-978, with affinities tuned to optimize the killing of low-CD19 expressing tumor cells. CLN-978 bound to CD19 on B cells with picomolar affinity, and to CD3ε on T cells with nanomolar affinity. A serum albumin binding domain was incorporated to extend serum half-life. In this setting, we biophysically characterize and report the activities of CLN-978 in cell co-culture assays, multiple mouse models and non-human primates.

Results:

Human T cells redirected by CLN-978 could eliminate target cells expressing less than 300 copies of CD19 on their surface. The half-life extension and high affinity for CD19 led to significant antitumor activity in murine lymphoma models at very low doses of CLN-978. In primates, we observed a long serum half-life, deep and sustained depletion of normal B cells, and remarkable tolerability, in particular, reduced cytokine release when CLN-978 was administered subcutaneously.

Conclusions:

CLN-978 warrants further exploration. An ongoing clinical phase 1 trial is investigating safety, pharmacokinetics, pharmacodynamics, and the initial therapeutic potential of subcutaneously administered CLN-978 in patients with non-Hodgkin’s lymphoma.

项与 CLN-978 相关的新闻（医药）

2024-11-14

·GlobeNewswire-Health Care

Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024

Cullinan will present new in vitro preclinical data that provide further strong rationale for broad clinical development of CLN-978 in autoimmune diseases Cullinan will share details of global Phase 1b study in moderate to severe systemic lupus erythematosus Company to host in-person investor event on Saturday, November 16, 2024, at 8 p.m. ET CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, will present new preclinical data for CLN-978, its novel CD19xCD3 T cell engager. These data and the study schema for a planned Phase 1b study in patients with moderate to severe systemic lupus erythematosus (SLE) will be presented at the annual meeting of the American College of Rheumatology (ACR), ACR Convergence 2024, being held in Washington, D.C., November 14-19. These data will be shared in a poster presentation on November 16, 2024, 10:30 a.m.-12:30 p.m. Eastern Time (Poster Session A, Poster Number 0003). Cullinan will also have a Booth (#2304) in the Exhibit Hall. CLN-978 Preclinical Data New in vitro preclinical data show CLN-978 induced similar T cell activation, target B cell depletion, and cytokine production in human peripheral blood mononuclear cells (PBMC) derived from patients with SLE (n=12) or rheumatoid arthritis (RA) (n=9) as compared to healthy volunteers (n=11). These studies collectively suggest that the previously observed cytokine window observed in B-NHL model systems, potentially resulting in a broad therapeutic index, is expected to be preserved in SLE and RA patients. "These new preclinical data further demonstrate that CLN-978 is a highly potent T cell engager. With the ability to be subcutaneously delivered, CLN-978 offers off-the-shelf convenience while achieving significant B cell depletion, supporting its potential as a promising new therapeutic option for autoimmune diseases,” said Jeffrey Jones, MD, MBA, Chief Medical Officer of Cullinan Therapeutics. "With regulatory clearances in the U.S. and Australia, we are launching a global Phase 1b clinical trial of CLN-978 in SLE, collaborating closely with investigators and the patient community in our mission to establish new standards of care for patients.” CLN-978 Global Clinical Development Plan In October, Cullinan Therapeutics announced U.S. Food and Drug Administration clearance of an Investigational New Drug Application for its global Phase 1 clinical trial to evaluate CLN-978 for the treatment of patients with moderate to severe SLE to proceed in the United States. Cullinan previously announced Human Research Ethics Committee approval to initiate the global clinical trial in Australia (NCT06613360). The trial will enroll patients with a Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score of eight or greater and who have had an inadequate response to at least two treatments, including one immunosuppressive or biologic standard-of-care agent. Part A is a dose escalation phase using a modified single-ascending dose design to determine a recommended target dose for further development. Part A is planned to explore target dose levels of 10, 20, 30, and 45 micrograms (mcg) in a stepwise ascending fashion, enrolling at least three patients in each cohort. Dose levels above 10 mcg will incorporate a step-up dose of 10 mcg administered on Day 1 followed by administration of the higher cohort target dose on Day 8. Part B is a dose expansion phase which will explore two or more recommended dose schedules informed by data from Part A of the study. The primary objective of the study is to evaluate the safety of CLN-978 for treatment of active moderate to severe SLE. Secondary objectives include pharmacokinetics, B cell kinetics, immunogenicity, and clinical activity. Initial clinical data are expected in the fourth quarter of 2025. Live Investor Event Cullinan will host an in-person event for analysts and institutional investors on Saturday, November 16, 2024, at 8 p.m. ET, during which members of Cullinan’s management team will be available for discussion. The event will also feature a clinician and thought leader discussion, followed by a question-and-answer session. Investors and analysts are invited to register to attend in person by emailing Nick Smith, Director of Investor Relations (nsmith@cullinantx.com). About CLN-978 CLN-978 is a novel, highly potent CD19xCD3 bispecific T cell engager. CLN-978 triggers redirected lysis of CD19-expressing target cells in vitro and in vivo. CLN-978 is engineered to achieve very high affinity binding to CD19 to efficiently target B cells, including those with very low CD19 levels. Small in molecular size (65 kDa), CLN-978 contains two single-chain variable fragments, one binding with very high affinity to the CD19 target and the other binding to CD3 on T cells, and a single-domain antibody binding to human serum albumin to extend serum half-life. CLN-978 was developed by an internal Cullinan team and is a wholly owned asset. CLN-978 has the potential to offer a convenient, off-the-shelf, subcutaneously delivered therapeutic option for patients with autoimmune diseases such as SLE and rheumatoid arthritis. About Systemic Lupus Erythematosus Systemic lupus erythematosus (SLE) is a chronic, heterogeneous autoimmune disease in which the immune system attacks a patient’s own tissues. The most common manifestations of SLE include skin rashes, arthritis, swelling in the feet, and around the eyes, extreme fatigue, and low fevers. Lupus nephritis (LN) is a kidney disease and the most common severe manifestation of SLE. Approximately 40% of patients with SLE develop LN, which has a 10-year 30% mortality rate.1,2 The prevalence of SLE in the US is estimated at 160,000 to 320,000 cases and SLE affects approximately 3.4 million individuals globally.3,4 SLE is more prevalent in women and people of color. It occurs most often in people between the ages of 15 and 45 years, but can occur in childhood or later in life as well. Currently available treatments do not routinely induce treatment-free remission, and most patients require lifelong immune suppression that treats symptoms without modifying the course of disease. About Cullinan Therapeutics Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company dedicated to creating new standards of care for patients. Cullinan has strategically built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both autoimmune diseases and cancer. Cullinan’s portfolio encompasses a wide range of modalities, each with the potential to be best and/or first in class. Anchored in a deep understanding of oncology, immunology, and translational medicine, we create differentiated ideas, identify the most appropriate targets, and select the optimal modality to develop transformative therapeutics across a wide variety of autoimmune and cancer indications. We push conventional boundaries from candidate selection to differentiated therapeutic, applying rigorous go/no go criteria at each stage of development to fast-track only the most promising molecules to the clinic and, ultimately, commercialization. With deep scientific expertise, our teams exercise creativity and urgency to deliver on our promise to bring new therapeutic solutions to patients. Learn more about Cullinan at https://cullinantherapeutics.com/, and follow us on LinkedIn and X. Forward Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding the company’s beliefs and expectations regarding: our preclinical and clinical developments plans and timelines for CLN-978, the clinical and therapeutic potential of CLN-978, our plans regarding future data presentations, and other statements that are not historical facts. The words “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “plan,” “potential,” “project,” “pursue,” “will,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events and are subject to known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, but are not limited to, the following: uncertainty regarding the timing and results of regulatory submissions; the risk that any INDs or other global regulatory submissions we may file with the United States Food and Drug Administration or other global regulatory agencies are not cleared on our expected timelines, or at all; the success of our clinical trials and preclinical studies; the risks related to our ability to protect and maintain our intellectual property position; the risks related to manufacturing, supply, and distribution of our product candidates; the risk that any one or more of our product candidates, including those that are co-developed, will not be successfully developed and commercialized; the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies; and the success of any collaboration, partnership, license or similar agreements. These and other important risks and uncertainties discussed in our filings with the Securities and Exchange Commission, including under the caption “Risk Factors” in our most recent Annual Report on Form 10-K and subsequent filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change, except to the extent required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Moreover, except as required by law, neither the company nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made. Contacts:  Investors  Nick Smith  +1 401.241.3516  nsmith@cullinantx.com Media  Rose Weldon   +1 215.801.7644   rweldon@cullinantx.com Mahajan A et al. Lupus. 2020Hocaoglu M et al. Arthritis Rheumatol. 2023Tian J et al. Ann Rheum Dis. 2022Dall'Era M. In: Imboden J et al. CURRENT Diagnosis & Treatment: Rheumatology. 3rd ed. 2013

临床1期临床申请细胞疗法

2024-11-11

·BioPharmaDive

Fueling accelerated drug development in autoimmune diseases with a modality-agnostic approach

Recent extensive investment in oncologyparticularly immuno-oncologyhas driven scientific and medical breakthroughs delivering life-changing outcomes for many patients living with cancer.Scientific advances in understanding the immune system are driving renewed interest in autoimmune diseases, with insights now being applied to autoimmune disorders like systemic lupus erythematosus (SLE) and rheumatoid arthritis, where current therapies routinely fail to achieve treatment-free remission.1,2 Subsequently, many patients with these chronic diseases require lifelong immune suppression for symptom management, often without achieving long-term disease control.3,4The biotech industry, pursuing ideas holding the greatest potential impact on patient lives, is positioned to act quickly on emerging scienceaccelerating development of new standards of care. Companies like Cullinan Therapeutics are helping lead this groundswell in autoimmune diseases with a unique, modality-agnostic approach and collaboration with external experts, reflective of its innovation-without-borders philosophyseeking to bring forward only the most promising therapies. Strategy grounded in patient impactHowever, not all biotechs have the resources, teams, or agility to make quick, strategic decisions in an ever-adapting scientific landscape. For those that can, success hinges on addressing unmet needs as quickly as possible in diseases with significant potential for improved patient outcomes. This shift is already happening in autoimmune diseases. Strategies centered on B cell depletion have long been validated in both oncology and autoimmune disorders, given B cells role in immune system dysregulation.5,6 While TCE therapies have achieved lasting remissions in B cell malignancies, only recently has research suggested their disease-modifying potential in autoimmune diseases.7.8 This watershed moment renewed energy and investment in immunology. While many companies focused on advancing CAR T cell therapies, teams at Cullinan identified the broader utility of a different modalitytheir novel, highly potent CD19-specific TCE. With off-the-shelf convenience and subcutaneous delivery allowing flexible, repeat dosing (as needed), CLN-978 emerged as a differentiated, patient-friendly option being studied in clinical trials.9As new research surfaced, our scientific teams quickly evaluated whether we could make a meaningful difference for patients in this growing area of unmet need, said Jeff Jones, MD, MBA, Chief Medical Officer, Cullinan Therapeutics. Our modality-agnostic model gives us the agility to recalibrate based on scientific breakthroughs and ensure were focusing our pipeline on areas with the greatest need and potential for impact.Just six months after its strategic expansion into autoimmune diseases, Cullinan progressed its global development plan for CLN-978 to be studied in multiple clinical trials.10,11 In October, the U.S. Food and Drug Administration cleared Cullinans Investigational New Drug application to proceed with its global Phase 1 clinical trial of CLN-978 in moderate to severe SLE, representing the first development-stage CD19-specific TCE to receive U.S. clearance in autoimmune disease.12 This followed approval from a Human Research Ethics Committee in Australia in Septemberwhich marked the launch of the global trial.13 A second Phase 1 study in refractory rheumatoid arthritis is in development.Innovation without borders to progress new opportunitiesAdvancing new ideas offering the greatest potential patient benefit is only possible through cross-industry collaboration, including with institutional and advocacy partners worldwide. Lupus is a complex and heterogeneous disease. The disease can impact everyone differently and symptoms can change over time. Many patients try existing therapies, sometimes in combination, to achieve short periods of remission. Treatment solutions capable of delivering long-term remission would be very impactful, said Stacie Bell, Executive Vice President and lead of Lupus Therapeutics, the clinical affiliate of the Lupus Research Alliance. Success in treatment development requires collaboration with industry, especially in early clinical research, which drives life-changing innovations and potential curative therapies that those living with lupus are waiting for.Dr. Jones, a former academic physician, emphasizes that the best results come from engaging experts passionate about advancing science and improving lives through development of groundbreaking, investigational assets. Cullinans global clinical strategy reflects its innovation-without-borders ethos, enabling teams to secure alignment, validation, and support from leading institutions and patient advocacy and research groups as they work to progress CLN-978.The potential of anti-CD19 T cell engagers, including CLN-978, is incredibly excitingits an exhilarating time as a rheumatologist, said Anca Askanase, MD, MPH, Founder and Director of Columbia University's Lupus Center and the Director of Rheumatology Clinical Trials. These industry collaborations are likely to bring forward treatments that make a real difference for patients with autoimmune diseases.This moment presents an exciting convergencedecades of scientific progress intersecting with established clinical experience in practice-changing modalities. Companies with agile, multidisciplinary strategies that embrace emerging science are well-positioned to deliver transformational medicines in autoimmune diseases.References:1. Lupus Foundation of America. Lupus remission. 20222. Arthritis Foundation. Your RA is in Remission! Now What?3. Cleveland Clinic. Autoimmune Diseases. 20214. Lopez-Millan B et al. Nature. 20175. Zhang Z et al. Front Immunol. 20236. Mackensen A et al. Nat Med. 20227. Michaelson J & Baeuerle P J. Exp. Med. 20248. Mller F et al. N Engl J Med. 20249. Cullinan Therapeutics. Targeting CD19 With T Cell Engagers. 202410. Cullinan Therapeutics. Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases. Press release. 202411. Cullinan Therapeutics. Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus. Press Release. 202412. Cullinan Therapeutics. Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus. Press Release. 202413. Cullinan Therapeutics. Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus. Press Release. 2024 '

免疫疗法临床申请临床1期

2024-11-07

·GlobeNewswire-Health Care

Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Global Phase 1 study of CLN-978 in systemic lupus erythematosus (SLE) cleared to initiate in U.S. and Australia; initial clinical data expected in Q4 2025 CLN-619 on-track for initial expansion cohort data in endometrial and cervical cancers in Q2 2025 Zipalertinib pivotal Phase 2b study enrollment completed ahead of schedule; results expected mid-year 2025 CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today reported recent and anticipated business highlights and announced its financial results for the third quarter ended September 30, 2024. “We are making meaningful progress in executing our strategic plans for CLN-978 in autoimmune diseases while simultaneously advancing our oncology pipeline,” said Nadim Ahmed, Chief Executive Officer of Cullinan Therapeutics. “We have secured clearance from the U.S. Food and Drug Administration (FDA) for our IND application and Human Research Ethics Committee (HREC) approval in Australia to initiate our global Phase 1 study for CLN-978 in moderate to severe SLE. These important regulatory clearances position us to share initial clinical data for CLN-978 in the fourth quarter of 2025. We also continue to make significant progress in advancing our oncology portfolio, with data from two of our key programs expected in 2025. For CLN-619, we remain on track to share initial expansion data for endometrial and cervical cancers in the second quarter of 2025. We also completed enrollment of the pivotal Phase 2b study of zipalertinib ahead of schedule, and we plan to provide the results at mid-year 2025.” Portfolio Highlights Immunology CLN-978 (CD19xCD3 T cell engager): Systemic lupus erythematosus and rheumatoid arthritis The company obtained health authority approvals to initiate its global Phase 1 study in moderate to severe SLE, securing U.S. FDA clearance of its IND application and HREC approval in Australia. Cullinan plans to share initial clinical data for SLE in the fourth quarter of 2025. The company also continues to engage with other global health authorities to expand the planned country and site footprint.The company plans to initiate a sponsored clinical trial in rheumatoid arthritis (RA) in the second quarter of 2025. The trial will be designed and executed in collaboration with FAU Erlangen-Nuremberg in Germany and Università Cattolica del Sacro Cuore, Rome in Italy.Cullinan is presenting preclinical data at the upcoming American College of Rheumatology (ACR) Convergence 2024, taking place in Washington, D.C. from November 14-19, 2024. Oncology CLN-619 (Anti-MICA/MICB monoclonal antibody): Solid tumors and hematological malignancies In September, Cullinan dosed the first patient in a Phase 1 study of CLN-619 in patients with relapsed/refractory multiple myeloma.New biomarker and translational data from the monotherapy dose escalation portion of the Phase 1 study in solid tumors will be presented at the Society for Immunotherapy of Cancer (SITC) in November.The company continues enrollment of disease-specific expansion cohorts of its Phase 1 study in solid tumors, enrolling cervical, endometrial and non-small cell lung cancer (NSCLC) patients. Cullinan remains on track to report initial data in endometrial and cervical cancers in the second quarter of 2025.Notably, the company was issued a key composition of matter patent by the United States Patent and Trademark Office, which is expected to extend protection until at least 2041, excluding possible patent term extension. Zipalertinib (EGFR ex20ins inhibitor), collaboration with Taiho Oncology: EGFR ex20ins NSCLC At the European Society for Medical Oncology (ESMO) Congress in September, Cullinan presented positive REZILIENT1 results in patients with EGFR ex20ins NSCLC who have progressed on or after prior amivantamab treatment. Zipalertinib demonstrated a consistent objective response rate of approximately 40% and a manageable safety profile.In September, Cullinan successfully completed enrollment of the pivotal Phase 2b study ahead of schedule, which was originally planned for the end of this year. Cullinan plans to share the results of the pivotal Phase 2b study at mid-year 2025. Taiho continues enrollment of the pivotal study REZILIENT3 in 1L EGFR ex20ins NSCLC. CLN-049 (FLT3xCD3 T cell-engaging bispecific antibody): AML and MDS Following the clinical update in Q2 2024 and discontinuation of subcutaneous administration, enrollment continues with IV administration in the ongoing Phase 1 study in patients with relapsed/refractory AML and MDS. CLN-617 (IL-2 and IL-12 cytokine fusion protein): Solid tumors Enrollment continues in the ongoing Phase 1 study in patients with advanced solid tumors. Corporate Updates In the third quarter, the company added two rheumatology and immunology experts to its Scientific Advisory Board (SAB): Dr. Ricardo Grieshaber-Bouyer and Dr. Chaim Putterman. Dr. Grieshaber-Bouyer and Dr. Putterman’s expertise will further strengthen the company’s Scientific Advisory Board. Dr. Grieshaber-Bouyer is head of the clinical trial unit at FAU Erlangen-Nurnberg Rheumatology and Immunology Department and cares for patients with rheumatic and immune-mediated diseases, in particular in the context of emerging therapies such as T cell redirecting therapies.Dr. Putterman is Professor Emeritus of the Division of Rheumatology at Albert Einstein College of Medicine and Montefiore Medical Center, where his research focuses on mechanisms of autoimmunity, pathogenesis of kidney and neuropsychiatric disease in SLE, novel therapies for lupus, and SLE biomarkers. Third Quarter 2024 Financial Results Cash Position: Cash, cash equivalents, short- and long-term investments, and interest receivable were $639.0 million as of September 30, 2024. Cullinan continues to expect its cash resources to provide runway into 2028 based on its current operating plan.R&D Expenses: Research and development expenses were $35.5 million for the third quarter of 2024, compared to $33.8 million for the same period in 2023.G&A Expenses: General and administrative expenses were $13.3 million for the third quarter of 2024, compared to $11.0 million for the same period in 2023.Net loss: Net loss was $40.6 million ($0.69 per common share) for the third quarter of 2024, compared to $39.2 million ($0.91 per common share) for the same period in 2023. About Cullinan Therapeutics Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company dedicated to creating new standards of care for patients. Cullinan has strategically built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both autoimmune diseases and cancer. Cullinan’s portfolio encompasses a wide range of modalities, each with the potential to be best and/or first in class. Anchored in a deep understanding of oncology, immunology, and translational medicine, we create differentiated ideas, identify the most appropriate targets, and select the optimal modality to develop transformative therapeutics across a wide variety of autoimmune and cancer indications. We push conventional boundaries from candidate selection to differentiated therapeutic, applying rigorous go/no go criteria at each stage of development to fast-track only the most promising molecules to the clinic and, ultimately, commercialization. With deep scientific expertise, our teams exercise creativity and urgency to deliver on our promise to bring new therapeutic solutions to patients. Learn more about Cullinan at https://cullinantherapeutics.com/, and follow us on LinkedIn and X. Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding the company’s beliefs and expectations regarding: our preclinical and clinical developments plans and timelines for our product candidates, the clinical and therapeutic potential of our product candidates, the strategy of our product candidates, our research and development activities, our plans regarding future data presentations, our cash runway, and other statements that are not historical facts. The words “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “plan,” “potential,” “project,” “pursue,” “will,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events and are subject to known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, but are not limited to, the following: uncertainty regarding the timing and results of regulatory submissions; the risk that any INDs or other global regulatory submissions we may file with the United States Food and Drug Administration or other global regulatory agencies are not cleared on our expected timelines, or at all; the success of our clinical trials and preclinical studies; the risks related to our ability to protect and maintain our intellectual property position; the risks related to manufacturing, supply, and distribution of our product candidates; the risk that any one or more of our product candidates, including those that are co-developed, will not be successfully developed and commercialized; the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies; and the success of any collaboration, partnership, license or similar agreements. These and other important risks and uncertainties discussed in our filings with the Securities and Exchange Commission, including under the caption “Risk Factors” in our most recent Annual Report on Form 10-K and subsequent filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change, except to the extent required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Moreover, except as required by law, neither the company nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made. Cullinan Therapeutics, Inc.Selected Condensed Consolidated Balance Sheet Data(unaudited)(in thousands) September 30, 2024 December 31, 2023 Cash, cash equivalents, investments, and interest receivable $638,996 $468,264 Total assets $653,254 $484,182 Total current liabilities $24,204 $28,137 Total liabilities $25,392 $30,287 Total stockholders’ equity $627,862 $453,895 ` Cullinan Therapeutics, Inc.Consolidated Statements of Operations(unaudited)(in thousands, except per share amounts) Three Months Ended Nine Months Ended September 30, 2024 September 30, 2023 September 30, 2024 September 30, 2023Operating expenses: Research and development $35,506 $33,821 $102,411 $113,308 General and administrative 13,349 10,982 39,460 31,856 Total operating expenses 48,855 44,803 141,871 145,164 Impairment of long-lived assets — (440) — (440)Loss from operations (48,855) (45,243) (141,871) (145,604)Other income (expense): Interest income 8,384 5,880 22,148 15,710 Other income (expense), net (89) 180 (205) 356 Net loss (40,560) (39,183) (119,928) (129,538)Net loss attributable to noncontrolling interests — — (192) (179)Net loss attributable to common stockholders of Cullinan $(40,560) $(39,183) $(119,736) $(129,359) Net loss per share attributable to common stockholders of Cullinan: Basic and diluted $(0.69) $(0.91) $(2.30) $(3.15) Weighted-average shares used in computing net loss per share attributable to common stockholders of Cullinan: Basic and diluted 58,337 42,734 52,157 41,130 Contacts: InvestorsNick Smith+1 401.241.3516nsmith@cullinantx.com Media  Rose Weldon +1 215.801.7644 rweldon@cullinantx.com

临床2期临床1期临床结果免疫疗法临床申请

100 项与 CLN-978 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
系统性红斑狼疮	临床1期	-	Cullinan Oncology LLC	2024-11-01
复发性B细胞淋巴瘤	临床1期	美国	Cullinan Oncology LLC	2023-05-31
难治性成熟B细胞非霍奇金淋巴瘤	临床1期	美国	Cullinan Oncology LLC	2023-01-24
类风湿关节炎	临床前	美国	Cullinan Oncology LLC	2024-09-06
前体B细胞成淋巴细胞白血病淋巴瘤	临床前	美国	Cullinan Oncology LLC	-